Sorrento to file IND for anti-SARS-CoV-2 nasal drops

By The Science Advisory Board staff writers

Sorrento Therapeutics is filing an investigational new drug application (IND) with the U.S. Food and Drug Administration for its STI-2099 (Covi-Drops), an intranasal formula of a neutralizing antibody against SARS-CoV-2.

Sorrento will study the safety and pharmacokinetics of Covi-Drops in healthy volunteers and patients with mild COVID-19 in a phase I trial if the agency authorizes the IND.

The drops demonstrated a 100% neutralizing effect in vitro and in vivo. At very low doses, they prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in Syrian golden hamsters, according to preclinical data.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?